Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 1049-1057

  Liu, Dian Lei ^a   Bu, Heqi ^a   Li, Hong ^b   Chen, Hui ^a   Guo, Hong Chun ^a   Wang, Zhao Hong ^a   Tong, Hong Fei ^a   Ni, Zhong Lin ^a   Liu, Hai Bin ^a   Lin, Sheng Zhang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b Wenzhou Vocational College of Science and Technology   (China)

Author keywords

Emodin; Gemcitabine resistance; Pancreatic cancer; Reverse

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; CASPASE 9; CYTOCHROME C; EMODIN; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER MORPHOLOGY; CANCER RESISTANCE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG TUMOR LEVEL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROSCOPY; MITOCHONDRION; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EMODIN; HUMANS; MITOCHONDRIA; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 84863364968     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1285     Document Type: Article

References (37)

1. Rivera F, Lopez-Tarruella S, Vega-Villegas MA and Salcedo M: Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 35: 335-339, 2009.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007. (Pubitemid 46148091)
3. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
4. Burris HA, Moore MJ, Andersen J, Green MR, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
5. Yu C, Zhang X, Sun G, Guo X, et al: RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells. J Cell Mol Med 12: 2234-2249, 2008.
6. El Maalouf G, Le Tourneau C, Batty GN, Faivre S and Raymond E: Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat Rev 35: 167-174, 2009.
7. Tada M, Arizumi M, Nakai Y, Sasaki T, et al: Efficacy of gemci-tabine for locally advanced pancreatic cancer: comparsion with 5-fuorouracil-based chemoradiotherapy. Chemotherapy 54: 302-308, 2008.
8. Basu S, Ghosh A and Hazra B: Evaluation of the antibacterial activity of Ventilago madraspatana Gaertn., Rubia cordifolia Linn. and Lantana camara Linn.: isolation of emodin and physcion as active antibacterial agents. Phytother Res 19: 888-894, 2005. (Pubitemid 41665959)
9. Manojlovic NT, Solujic S, Sukdolak S, et al: Antifungal activity of Rubia tinctorum, Rhamnus frangula and Caloplaca cerina. Fitoterapia 76: 244-246, 2005. (Pubitemid 40326977)
10. Alves DS, Perez-Fons L, Estepa A, et al: Membrane-related effects underlying the biological activity of the anthraquinones emodin and barbaloin. Biochem Pharmacol 68: 549-561, 2004. (Pubitemid 38887437)
11. Mbwambo ZH, Apers S, Moshi MJ, et al: Anthranoid compounds with antiprotozoal activity from Vismia orientalis. Planta Med 70: 706-710, 2004. (Pubitemid 39178929)
12. Li HL, Chen HL, Li H, et al: Regulatory effects of emodin on NF-kappaB activation and inflammatory cytokine expression in RAW 264.7 macrophages. Int J Mol Med 16: 41-47, 2005.
13. Kitano A, Saika S, Yamanaka O, Ikeda K, Okada Y, et al: Emodin suppression of ocular surface inflammatory reaction. Invest Ophthalmol Vis Sci 48: 5013-5022, 2007. (Pubitemid 351260911)
14. Kuo YC, Tsai WJ, Meng HC, Chen WP, et al: Immune reponses in human mesangial cells regulated by emodin from Polygonum hypoleucum Ohwi. Life Sci 68: 1271-1286, 2001.
15. Cai J, RazzakA, Hering J, Saed A, et al: Feasibility evaluation of emodin (rhubarb extract) as an inhibitor of pancreatic cancer cell proliferation in vitro. J Parenter Enteral Nutr 32: 190-196, 2008. (Pubitemid 351464893)
16. Chen H, Wei WT, Guo YF, Liu A, et al: Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis. Oncol Rep 25: 1253-1261, 2011.
17. Jung HA, Chung HY, Yokozawa T, et al: Alaternin and emodin with hydroxyl radical inhibitory and/or scavenging activities and hepatoprotective activity on tacrine-induced cytotoxicity in HepG2 cells. Arch Pharm Res 27: 947-953, 2004. (Pubitemid 43073692)
18. Liu A, Chen H, Tong H, et al: Emodin potentiates the antitumor effects of gemcitabine in pancreatic cancer cells via inhibition of nuclear factor-kappaB. Mol Med Rep 4: 221-227, 2011.
19. Hansen MB, Nielsen SE and Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210, 1989. (Pubitemid 19132276)
20. Hao ZM, Li XH, Qiao TD, Du R, Hong L and Fan DM: CIAPIN1 confers multidrug resistance by upregulating the expression of MDR-1 and MRP-1 in gastric cancer cells. Cancer Biol Ther 5: 261-266, 2006.
21. Banerjee S, Wang Z, Kong D and Sarkar FH: 3,3'-Diindolyl-methane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 69: 5592-5600, 2009.
22. Gao S, Liu Q, Wang X, Lin B and Zhang S: Effects of Lewis Y antigen on the gene expression of multiple drug resistance-associated proteins in human ovarian cancer RMG-I-H cells. Med Oncol 27: 960-967, 2010.
23. Wang ZH, Chen H, Guo HC, Tong HF, et al: Emodin antitumor efficacy by the combination of emodin and gencitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo. Int J Oncol 39: 1123-1131, 2011.
24. Wei WT, Chen H, Ni ZL, Liu HB, et al: Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation. Int J Oncol 39: 1381-1390, 2011.
25. Wang W, Sun YP, Huang XZ, He M, Chen YY, et al: Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem Pharmacol 79: 1134-1140, 2010.
26. Li J, Liu PS, Mao HL, et al: Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro. Oncol Rep 21: 1605-1610, 2009.
27. Leonessa F and Clarke R: ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10: 43-73, 2003. (Pubitemid 36457239)
28. Takakuwa O, Oguri T, Ozasa H, Uemura T, Kasai D, et al: Over-expression of MDR1 in amrubicinol-resistant lung cancer cells. Cancer Chemother Pharmacol 68: 669-676, 2010.
29. Dong Y, Shao S, Hu J and Yang P: Reversal effect of Raf-1/Mdr-1 siRNAs co-transfection on multidrug resistance in KBv200 cell line. Oral Oncol 45: 991-997, 2009.
30. Bentires Alj M, Barbu V, Fillet M, et al: NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22: 90-97, 2003. (Pubitemid 36152887)
31. Chen C, Shen HL, Yang J, Chen QY and Xu WL: Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib. J Cancer Res Clin Oncol 137: 9-17, 2011.
32. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89: 1845-1853, 1997.
33. Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999. (Pubitemid 29407357)
34. Qi FH, Inagaki Y, Gao B, Cui X and Xu HL: Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways. Cancer Sci 102: 951-958, 2011.
35. Leger DY, Liagre B and Beneytout JL: Role of MAPKs and NF-kappaB in diosgenin-induced megakaryocytic differentiation and subsequent apoptosis in HEL cells. Int J Oncol 28: 201-207, 2006.
36. Bachmeier B, Fichtner I, Killian PH, Kronski E, et al: Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells. PLoS One 6: e20550, 2011.
37. Kumar MV, Shirley R, Ma Y and Lewis RW: Role of genomics-based strategies in overcoming chemotherapeutic resistance. Curr Pharm Biotechnol 5: 471-480, 2004. (Pubitemid 39317614)